Caracterización exhaustiva del genotipo molecular e inmunofenotipo del cáncer de pulmón no microcítico
Lung cancer is the second most frequent malignancy in incidence and the leading cause of cancer related mortality. Non-small cell lung cancer (NSCLC) accounts for 85% of the cases and includes three subtypes: lung adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC). Ea...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | español |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/101461 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/101461 |
| Access Level: | acceso abierto |
| Palabra clave: | 616.24-006.04(043.2) Piulmones Lungs Cancer Neumología Oncología 3205.08 Enfermedades Pulmonares |
| Sumario: | Lung cancer is the second most frequent malignancy in incidence and the leading cause of cancer related mortality. Non-small cell lung cancer (NSCLC) accounts for 85% of the cases and includes three subtypes: lung adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC). Each variety presents distinct underlying genomic alterations. The prognosis of this disease has been markedly determined by the frequent late stage at diagnosis and the scarcity of effective systemic treatments. Lately, targeted therapy for oncogene driven NSCLCs, and immunotherapy with PD-1/PD-L1 inhibitors have shifted NSCLC management, showing remarkable benefits in treated patients. The benefit fro mimmune checkpoint inhibitors, particularly in the long term, is however not universal but restricted to a subset of patients. The development of predictive biomarkers in this setting has been challenging and recognized as a major unmet need as at present only PD-L1expression is extensively used, although its performance is far from ideal... |
|---|